Computer Aided Drug Discovery Market

Over 30% of the total cost invested in developing a new drug can be saved by utilizing in silico services. However, this is highly variable and is dependent upon the nature of drug discovery projects

-- CEO, a US-based small-sized company

Computer Aided Drug Discovery Market Overview

The computer aided drug discovery market is estimated to be worth $29 million in 2020 and is expected to grow at CAGR of 15.6% till 2030.

The process of drug development, beginning from the discovery of a pharmacological lead to its commercial launch, is estimated to take around 10-15 years, involving capital investments in the range of USD 4-10 billion. Moreover, it is well-known that only a small proportion of leads, which are selected for further investigation during the initial stages of research, are actually translated into product candidates for clinical research studies.

Over time, the complexities of drug discovery, have increased; this is especially true for large molecules, which are inherently more complex than conventional small molecule drugs. As a result, there has been a direct rise in overall research and development (R&D) expenditure in the pharmaceutical / biotechnology sector. Specifically, in 2019, the global R&D spending was estimated to be around USD 182 billion, with over 16,000 drug molecules reported to have been investigated. Presently, the industry is currently under tremendous pressure to identify ways to cope with rising capital requirements in drug discovery research and actively avoid losses owing to failed drug development programs. In addition, there has been an evident increase in regulatory stringency, which has made the drug approval process, especially for large molecules, significantly more difficult.

During the last several years, several computational drug discovery tools have been developed and introduced for enabling the identification, selection and optimization of pharmacological lead candidates. Currently, there are several computer aided drug discovery approaches available such as structure based drug design, fragment based drug discovery and ligand based drug discovery for multi-target drug design. The predictive power of these computational drug discovery tools has been proven to be very advantageous, allowing researchers to bypass the random screening of billions of molecules across hundreds of large molecule targets. According to industry experts, almost 35% of the total cost and time invested in developing a new drug can be saved by adopting computational drug discovery (CADD) approach. As a result, companies offering computer aided drug discovery services, such as computer-aided drug design (CADD), molecular modeling and quantitative structure–activity relationship (QSAR), have now become an important part of the pharmaceutical industry. In future, drug developers, especially those focused on the development of large molecules, are likely to continue relying on outsourcing for a significant part of their respective drug discovery and development operations. Owing to this, the computer aided drug discovery market is likely to witness substantial market growth during the forecast period.

Key Companies in Computer Aided Drug Discovery Market

Examples of key companies engaged in computer aided drug discovery market (which have also been profiled in this market report; the complete list of companies is available in the full report) include BioDuro, Creative Biostructure, GenScript, LakePharma, Abzena, BioNTech, Sygnature Discovery, ChemPartner, Sundia MediTech and Viva Biotech. This market report includes an easily searchable excel database of all the companies providing computer aided drug discovery services, worldwide.

Recent Developments in Computer Aided Drug Discovery Market

Several recent developments have taken place in the field of computer aided drug discovery market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

• In July 2025, Optibrium secured a multi-million-pound financing package from Shawbrook Bank to accelerate product development and expand its global footprint in pharmaceutical and biotech sectors.

Scope of the Computer Aided Drug Discovery Market Report

The “Computer Aided Drug Discovery Market: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug Discovery, Fragment Based Drug Discovery, Ligand Based Drug Discovery, Target Based Drug Discovery, Interface Based Drug Discovery Approaches)" market report features an extensive study on the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the computer aided drug discovery market. The market research report features an in-depth analysis, highlighting the capabilities of various industry stakeholders.

In addition to other elements, the market research report includes:

• A detailed review of the overall landscape of companies offering in silico drug discovery services for large molecules, including information on year of establishment, company size, location of headquarters, type of business model used (contract service providers (CROs), computational drug discovery software / technology providers, consulting service providers and training service providers), number of drug discovery step(s) for which the company offers services involving the use of in silico approaches (target identification, target validation, hit generation, hit-to-lead and lead optimization), type of large molecules(s) handled (antibodies (monoclonal antibodies, bispecific antibodies, polyclonal antibodies, antibody drug conjugates (ADCs), antibody fragments, single domain antibodies, antisense antibodies and others), proteins (fusion proteins, protein fragments, enzymes and hormones), peptides, cell therapies, gene therapies, vectors and nucleic acids), type of in silico approach used (structure-based drug design (SBDD), fragment-based drug design (FBDD), target-based drug design (TBDD), ligand-based drug design (LBDD) and interface-based drug design (IBDD)), type of in silico service(s) offered (virtual screening, molecular docking, molecular modeling, scaffold hopping and 8+ services), and type of clientele served (pharmaceutical / biotechnology companies and academic / research institutes).
• Insights on contemporary market trends, depicted using four schematic representations, which include [A] a logo landscape of the industry players engaged in this domain, distributed based on the basis of location of their company size (small (1-50 employees), mid-sized (51-200 employees) and large (>200 employees)) and respective headquarters, [B] a tree map representation of in silico service providers, featuring a distribution of stakeholders on the basis of the company size and drug discovery steps, [C] a world map representation, highlighting the key hubs with respect to outsourcing activity within this domain, and [D] an insightful grid analysis, presenting the distribution of companies based on the type of large molecule, in silico approach used and type of clientele.
• Elaborate profiles of key industry players that offer a wide range of in silico drug discovery services, featuring a brief overview of the company (including details related to year of establishment, company size, location of headquarters and key members of the executive team), funding and investment information (if available), in silico-based service(s) portfolio) and an informed future outlook.
• A detailed peer group-based benchmarking analysis, comparing the involved players based on several relevant parameters, such as the experience of the company, number of drug discovery step(s), number of in silico service(s) offered, number of large molecule(s) for which the aforementioned services are offered and type of clientele.
• An insightful competitiveness analysis featuring a four-dimensional bubble chart, highlighting the key players in this domain on the basis of the strength of their respective service portfolios, taking into consideration the experience of a service provider, number of drug discovery services offered and number of large molecules, for which the aforementioned services are offered.
• A detailed analysis assessing the current opportunity within in silico drug discovery services market, comparing the number of pipeline products and current market size across different types of large molecules, and the availability and capabilities of affiliated in silico drug discovery service providers.
• A discussion on the various business strategies that can be adopted by in silico drug discovery service providers in order to maintain a competitive edge in this industry, based on the different types of large molecules handled and the technical expertise of service providers, in terms of capabilities across different steps of drug discovery.
• An insightful analysis highlighting the cost saving potential associated with the use of in silico approaches in the drug discovery process.
• A case study comparing the key challenges associated with the discovery and production of large molecules, affiliated product development timelines, and manufacturing protocols, with those of small molecule drugs.
• Insights from an industry-wide survey, featuring inputs solicited from various experts who are directly / indirectly involved in providing in silico services for discovery of large molecule drugs.
• A discussion on the upcoming computational approaches (such as AI in oncologyand cloud services) that are being adopted for drug discovery purposes and are likely to impact early stage research over the coming years.
• A case study highlighting several non-computational methods / technologies, which are considered to be of significant importance to the overall drug discovery process.

The key objective of computer aided drug discovery market report is to provide a detailed market analysis in order to estimate the existing market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunity for computer aided drug discovery market during the forecast period. Based on several parameters, such as number of large molecules based drug discovery projects, adoption of in silico services for drug discovery and outsourcing profile, we have provided informed estimates on the likely evolution of the market for the forecast period 2020-2030. The market report also provides details on the likely distribution of the current and forecasted opportunity across [A] key step(s) of drug discovery (target identification, target validation, hit generation, hit-to-lead and lead optimization), [B] type of large molecule (antibodies, proteins, peptides, nucleic acids and vectors), [C] company size (small, mid-sized and large), [D] therapeutic area (autoimmune disorders, blood disorders, cardiovascular disorders, gastrointestinal and digestive disorders, hormonal disorders, HIV / AIDS, infectious diseases, metabolic disorders, mental disorders, musculoskeletal disorders, neurological disorders, oncological disorders, respiratory disorders, skin disorders, urogenital disorders and others), [E] type of clientele (pharmaceutical / biotechnology companies and academic / research institutes), and [F] key geographical regions (North America (the US and Canada), Europe (Italy, Germany, France, Spain and rest of Europe) and Asia-Pacific (China, India and Japan), along with the rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this market report were also influenced by inputs solicited via a survey and discussions held with senior stakeholders in the industry. The market research report features detailed transcripts of discussions held with the following individuals (in alphabetical order):

• John L Kulp (Chief Executive Officer and Chief Technical Officer, Conifer Point)
• Sven Benson (Founder, candidum)
• Mark Whittaker (Senior Vice President, Evotec)
• Edelmiro Moman (Scientific Consultant and Teacher, ProSciens)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.
 

Frequently Asked Questions

Question 1: What is computer aided drug discovery?

Answer: Computer aided drug discovery refers to the process of identifying potential therapeutic candidates for various therapeutic areas with improved efficiency and accuracy.

Question 2: How big is the computer aided drug discovery market?

Answer: The computer aided drug discovery market size is estimated to be worth $29 million in 2020.

Question 3: What is the projected market growth of the computer aided drug discovery market?

Answer: The computer aided drug discovery market is expected to grow at compounded annual growth rate (CAGR) of 15.6% during the forecast period 2020 – 2030.

Question 4: Who are the leading companies in the computer aided drug discovery market?

Answer: Examples of key companies engaged in computer aided drug discovery market (which have also been profiled in this market report; the complete list of companies is available in the full report) include BioDuro, Creative Biostructure, GenScript, LakePharma, Abzena, BioNTech, Sygnature Discovery, ChemPartner, Sundia MediTech and Viva Biotech.

Question 5: What is the cost saving potential of using computer aided drug discovery methods?

Answer: Almost 35% of the total cost and time invested in developing a new drug can be saved by adopting computer aided drug discovery methods.

Question 6: How many companies are currently engaged in the computer aided drug discovery market?

Answer: Over 90 companies are currently engaged in the computer aided drug discovery market offering drug discovery services for biologics.